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“Three billion bases of sequence can be put on a single compact 
disk (CD), and one will be able to pull a CD out of one’s pocket 
and say, ‘Here is a human being; it’s me!’” 
Walter Gilbert in Vision of the Grail1 
 
“It’s been a growing conviction of mine that biologists have a 
whole other way of talking to each other in the lab than they do 
to the public.” 
Evelyn Fox Keller2 
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TORRANCE LF CHECK.WEB (DO NOT DELETE) 3/9/2010  11:47 AM 
158 MINN. J. L. SCI. & TECH. [Vol. 11:1 
E.  GENE AS PROGRAM ............................................... 169 
F.  THE GENE CONCEPT UNRAVELS ....................... 170 
III.  GENE PATENTS .............................................................. 175 
A.  RECOMBINANT DNA ............................................. 175 
B.  PATENTS ON GENES ............................................. 176 
C.  GENES IN PATENTS .............................................. 178 
IV.  GENE TALK ...................................................................... 181 
A.  THE BIOTECHNOLOGY INDUSTRY .................... 181 
B.  THE RISE OF GENE TALK .................................... 182 
C.  GENE TALK AND GENE PATENTS ...................... 184 
V.  CONCLUSION .................................................................... 190 
 
Since the existence of a discrete unit of heredity was first 
proposed by Gregor Mendel, scientific concepts of the “gene” 
have undergone rapid evolution. Beyond obvious epistemic and 
operational importance to the scientific community, changing 
gene concepts have exerted strong effects on institutions such 
as medicine, the biotechnology industry, politics, and the law. A 
particularly rich example of this is the interplay between gene 
concepts and patent law. Over the last century, biology has ela-
borated gene concepts that variously emphasized genes as dis-
cretely material, genes as information, and genes as extremely 
complex. By contrast, patent law has steadily adhered to a 
simpler, more stable concept of the gene since the advent of 
gene patents in the late 1970s. In fact, while the biology com-
munity3 has increasingly engaged in vigorous internal debate 
regarding the gene’s complexity and uncertainty, it has tended 
simultaneously to emphasize the simplicity and certainty of the 
gene to constituencies outside the biology community, most 
notably the United States Patent and Trademark Office 
(USPTO) and the Federal courts. Rather than allow gene con-
cepts to become contested by constituencies outside biology, the 
biology community appears to have used its authority to main-
tain a portrayal of the gene that facilitates the appropriation of 
rents from genes through the patent system. This use of “gene 
talk” has undergirded the growth of biotechnology into a power-
ful industry that has economically rewarded investors, academ-
ic institutions, and biologists. Not only may gene talk have faci-
litated the patenting of genes, but the prominence of gene 
patents describing a relatively simpler gene concept may have 
                                                          
 3. “Biology community” is used hereafter to describe the professional bi-
ologists, whether in academia, biotechnology, or the government. 
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fed back into biological science to promote a simpler, and more 
patentable, concept of the gene even among members of the bi-
ology community. 
I.  INTRODUCTION 
The concept of the “gene” has undergone tremendous trans-
formation over the course of the last century. It began its life as 
a hypothetical mechanism for transferring characters4 from one 
generation to the next. A flurry of experimentation by Morgan 
and other early “classical” geneticists, whose results revealed a 
satisfying predictability to the inheritance of characters, caused 
the inchoate and hypothetical gene to coalesce into a unit pos-
sessing substantiality and materiality.5 The materiality of the 
gene was grounded even more firmly by the discovery that 
genes were made of a specific chemical, that is, deoxyribonucle-
ic acid (“DNA”). The discovery of the double-helical structure of 
DNA by James Watson and Francis Crick, along with the im-
plications of the double helix structure for the existence of a 
“genetic code,” represented the high-water mark of the material 
gene.6 
The breaking of the genetic code suggested a new characte-
ristic of the gene: information. Genes were portrayed as carry-
ing information encoded by their constituent nucleotides.7 In 
fact, the characterization of the operon8 by Jacob and Monod 
suggested that the information carried by genes was not simply 
information, but programmatic in nature.9 Similar to computer 
software, the information encoded by a gene was viewed as op-
erating like an algorithm, instructing the chemical machinery 
of the cell to make structures and perform functions in particu-
lar orders with specific effects. 
                                                          
 4. The term “character” is herein used in its taxonomic sense to denote 
any characteristic or feature of an organism, including those characteristics or 
features related to morphology, physiology, and behavior. 
 5. See discussion infra Part II.B. 
 6. See discussion infra Part II.C. 
 7. See discussion infra Part II.D. 
 8. BENJAMIN LEWIN, GENES IX 858 (2008) (“An operon is a unit of bac-
terial gene expression and regulation, including structural genes and control 
elements in DNA recognized by regulator gene product(s).”);  EVELYN FOX 
KELLER, THE CENTURY OF THE GENE 57 (2000) (The word “operon” denotes “a 
linked cluster of regulatory elements and structural genes whose expression is 
coordinated by the product of a regulator gene situated elsewhere in the ge-
nome.”) 
 9. See discussion infra Part II.E. 
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Methods of determining the specific nucleotides located on 
particular genes developed substantially in the 1970s with the 
invention of relatively rapid DNA sequencing technologies.10 
The ability to sequence genes rapidly created a flood of DNA 
sequence data. Meanwhile, recombinant DNA technology al-
lowed genes and gene fragments to be excised from one location 
in a genome, and then spliced into a different genomic location, 
either in the same or a different individual organism, or even in 
a different type of organism.11 Gene concepts emphasizing par-
ticulate materiality, information content, or encoded algorith-
mic programs, coupled with DNA sequencing and recombinant 
DNA technologies, facilitated a view among biologists, and oth-
ers, that one could “invent” DNA-based innovations just as one 
could write software to run on a computer.12 Newly-sequenced 
genes, as long as they had been isolated and purified, could now 
be conceived of as inventions ripe for patent protection.13 After 
the landmark decision in Diamond v. Chakrabarty, the United 
States Patent and Trademark Office (USPTO) began regularly 
to issue patents claiming sequenced genes.14 
Just prior to the issuance of the first gene patent in 1981, 
the simple linearity of the prevailing gene concept was fatally 
challenged by the discovery that eukaryotic polypeptides 
tended to be encoded by physically separate and noncontiguous 
stretches of DNA. Many genes, rather than consisting of sim-
ple, contiguous linear arrays of nucleotides, like beads strung 
together on a necklace, more accurately resembled fragments of 
beads (“exons”) dispersed throughout a necklace, and separated 
by non-gene-related sequences of nucleotides (“introns”).15 
However, to a large degree, biologists do not acknowledge the 
growing complexity of the gene concept when claiming genes in 
patents (hereinafter “gene patents”). USPTO regulations and 
judicial opinions, as they relate to gene patents, do not reflect 
this complexity either.16 In fact, neither gene patents nor judi-
cial opinions considering gene patents tend even to consider 
gene concepts or definitions. 
Meanwhile, debates about what a “gene” really is have 
                                                          
 10. See discussion infra Part II.F. 
 11. See discussion infra Part II.C. 
 12. See discussion infra Part II.F. 
 13. See discussion infra Part III.B. 
 14. See discussion infra Part III.B. 
 15. See discussion infra Part II.F. 
 16. See discussion infra Part III.B. 
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raged within the biology community. Since the first gene pa-
tents issued early in the 1980s, the gene concept has decayed 
towards incoherence. Evidence that genes may not only possess 
introns and exons, but that they sometimes overlap each other, 
encode products in multiple reading frames, and even encode 
products in both directions, has led many biologists, including 
some very prominent in the field, to conclude that the very idea 
of a “gene” is no longer useful.17 In the meantime, patenting 
genes has become routine for geneticists in both industry and 
academia. Encouraged by the Bayh-Dole Act, universities have 
become fertile sources of gene patents, and have thereby earned 
vast sums of money from licensing these gene patents to the 
biotechnology industry. The biotechnology industry itself, much 
of whose market value is undergirded by gene patents rather 
than actual commercial products, has also contributed to the 
flood of gene patent applications.18 
Growing incoherence in the biological understanding of 
what a gene might be, and of what gene concept can best reflect 
the empirical evidence, would seem to threaten the continued 
availability of patents claiming genes. After all, the disclosure 
requirements of patent law preclude the patenting of any in-
vention that cannot be adequately and accurately described.19 
Yet, gene patents tend to include minimal disclosure defining 
what genes are or describing claimed genes beyond recitation of 
their DNA sequences and putative utilities.20 Gene patents cer-
tainly do not teach the controversy surrounding gene concepts. 
This raises the question of whether patent applications that 
claim genes or gene-related inventions, but whose specifica-
tions oversimplify or simply ignore gene definitions, should is-
sue as patents. 
This article argues that the rhetorical portrayal of genes as 
relatively simple and predictable entities can explain, at least 
in part, the failure of gene patents or judicial opinions about 
gene patents to reflect the controversy and complexity of the 
biological understanding of genes. Evelyn Fox Keller coined the 
phrase “gene talk” to describe the rhetorical practices of con-
versing about genes both among biologists and between biolo-
gists and non-biologists. Gene talk may be employed in re-
                                                          
 17. See discussion infra Part III.C. 
 18. See discussion infra Part VI.A. 
 19. 35 U.S.C. §112, para 1 (2008). 
 20. See discussion infra Part II.B. 
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sponse to cultural, institutional, and economic imperatives that 
create strong incentives to justify property (that is, patent) 
rights in genes.21 Gene talk provides a useful shorthand for dis-
cussing a scientific concept whose meaning inspires tremend-
ous disagreement among biologists; by using the word “gene” 
loosely and contextually as a conceptual placeholder, biologists 
have been able to elucidate much about genetics. However, the 
biology community has also used gene talk successfully to fos-
ter enthusiasm, respect, and trust outside the biology commu-
nity for the power and potential of genes without communicat-
ing the prodigious scientific uncertainty that surrounds the 
structure, function, and even the existence of genes. Gene talk 
in the context of gene patents could even influence gene con-
cepts internal to the biology community. 
II.  HISTORY OF THE GENE CONCEPT 
A.  UNIT OF HEREDITY 
The Origin of Species by Means of Natural Selection revo-
lutionized biology by suggesting not only that lineages of organ-
isms change their characters over time (that is, they evolve) but 
by offering a causal mechanism for these changes (that is, nat-
ural selection).22 Nevertheless, Darwin left a significant ques-
tion unanswered: what hereditary unit is associated with the 
characters of organisms? Although he did suggest that a “gem-
mule” might be a unit of “pangenesis,” Darwin left to others the 
task of elaborating a coherent concept of a unit of heredity. 
Darwin never even knew the word “gene” because it was not 
coined until more than twenty years after his 1882 death. 
It took Gregor Mendel, an Augustinian monk who worked 
contemporaneously with Darwin, to elucidate the fundamental 
system of genetic inheritance. Mendel imagined a unit of hered-
ity that he called the “Elemente.”23 Though his discoveries 
would later form one of the bases of modern genetics, the con-
trast between the public reception of Mendel’s ideas and Dar-
win’s is remarkable: On the Origin of Species by Means of Nat-
ural Selection attracted immediate international attention, 
while Mendel’s research remained obscure until translated 
                                                          
 21. See EVELYN FOX KELLER, THE CENTURY OF THE GENE 10 (2000). 
 22. See generally CHARLES DARWIN, ON THE ORIGIN OF SPECIES BY MEANS 
OF NATURAL SELECTION (1859). 
 23. See KELLER, supra note 21, at 19. 
TORRANCE LF CHECK.WEB (DO NOT DELETE) 3/9/2010  11:47 AM 
2010] GENE CONCEPTS 163 
from the original German and published in English in 1901.24 
Soon after this rediscovery of Mendel’s research, Wilhelm Jo-
hannsen provided a name for the fundamental unit of heredity, 
the “gene,” a term he derived from the last syllable of Hugo de 
Vries’s “pangens.”25 
Biologists quickly adopted the concept of the “gene” as the 
unit of heredity, in part because it offered a solution to the 
problem of how many observable traits appeared to pass from 
generation to generation unchanged. “[T]he problem of trait 
stability was answered by assuming the existence of an inhe-
rently stable, potentially immortal, unit that could be trans-
ferred intact through the generations.”26 This unit was the 
gene. 
B.  GENE AS PARTICLE 
Long before Mendel’s research became widely known, and 
before the term “gene” had been coined, August Weismann had 
predicted several characteristics of the unit of heredity. As Kel-
ler explained: 
Whatever the mechanism by which a single cell reproduces the traits 
of the parent, Weismann assumed the existence of particulate, self-
reproducing elements that “determine” the properties of an organism; 
appropriately enough, he called these elements determinants. This 
assumption was hardly unique to Weismann—in fact, Darwin himself 
had hypothesized the existence of some such elements (his gem-
mules).27 
According to Weismann, determinants (that is, genes) were 
not inchoate, but, rather, possessed discrete materiality. Specif-
ically, his determinants were of “a definite chemical, and above 
all, molecular composition.”28 A contemporary, Hugo de Vries 
echoed Weismann’s materiality hypothesis, explaining that 
“[j]ust as physics and chemistry go back to molecules and 
atoms, the biological sciences have to penetrate to these units 
in order to explain, by their combinations, the phenomena of 
                                                          
 24. See generally Gregor Mendel, Experiments in Plant Hybridisation, 26 
J. ROYAL HORTICULTURAL SOC’Y 1 (1901) (proving that certain pairs of diffe-
rentiating characters, the germ-cells of a hybrid, or cross-bred, are pure, being 
carriers and transmitters of either the one character or the other, not both). 
 25. KELLER, supra note 21, at 1–2. 
 26. Id. at 14. 
 27. KELLER, supra note 21, at 16. 
 28. August Weismann, The Continuity of the Germ-Plasm as the Founda-
tion of a Theory of Heredity, in ESSAYS UPON HEREDITY AND KINDRED 
BIOLOGICAL PROBLEMS 161, 168 (Edward B. Poulton et al. eds., 1889). 
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the living world.”29 
Thomas Hunt Morgan was the first great experimental ge-
neticist since Mendel. In his “Fly Room” at Columbia Universi-
ty, Morgan established the fruit fly, Drosophila melanogaster, 
as the experimental organism of choice for studying genetics, 
and empirically that genes were located on chromosomes.30 By 
the time Morgan became the first geneticist to receive the No-
bel Prize in Medicine, in 1933, in part due to the work of his la-
boratory and alumni thereof, the majority of other geneticists 
had come to believe that “genes . . . [were] incontrovertibly real, 
material entities—the biological analogue of the molecules and 
atoms of physical science . . . .”31 Morgan suggested in his 1926 
book, The Theory of the Gene, that genes on chromosomes were 
“like beads on a string.”32 Morgan’s analogy to jewelry assumed 
significant influence over time, and “genes became generally 
viewed as discrete, stable, independently segregating units of 
inheritance lined up along a chromosome.”33 
C.  GENE AS SEQUENCE 
By the 1940s, the particulate theory of genes as discrete, 
physical structures on chromosomes had been widely accepted 
among geneticists. The gene’s structure and function was also 
assumed to be linked to the genes’ causal effects: 
Throughout the history of both classical and early molecular genetics, 
the gene was generally assumed to be not only a fixed and unitary lo-
cus of structure and function but also a locus of causal agency. T.H. 
Morgan, for example, regarded the idea that genes are the causal 
agents of development as so basic and so self-evident that an under-
standing of heredity did not require its elaboration.34 
However, lacking specific knowledge of gene structure, ge-
neticists were limited in understanding both gene function and 
causal agency. 
In 1943, Avery, McLeod, and McCarty identified “DNA as 
the carrier of biological specificity in bacteria.” 35 They proposed 
                                                          
 29. HUGO DE VRIES, INTRACELLULAR PANGENESIS 13 (C. Stuart Gager 
trans., The Open Court Publishing Co. 1910) (1889). 
 30. See JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 12–
13 (Beth Wilbur et al. eds., 6th ed. 2008). 
 31. KELLER, supra note 21, at 2. 
 32. THOMAS HUNT MORGAN, THE THEORY OF THE GENE 24 (1926). 
 33. Leonie Moyle, Most Ingenious: Troubles and Triumphs of the Century 
of Genes, 17 BIOLOGY AND PHIL. 715, 715–16 (2002). 
 34. KELLER, supra note 21, at 46. 
 35. Id. at 3. 
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that DNA “must be regarded not merely as structurally impor-
tant but as functionally active in determining the biochemical 
activities and specific characteristics of pneumococcal cells.”36 
Their conclusions were confirmed by Hershey and Chase in 
their 1952 “blender” experiment, which used radiolabeled ami-
no acids and nucleotides to detect whether proteins or nucleic 
acids were the carriers of heredity.37 
One year later, one of the greatest scientific advances in 
genetics allowed gene structure, function, and causal agency to 
be linked together intimately: elucidation of the double-helical 
structure of DNA. “[I]t was the triumphal announcement by 
James D. Watson and Francis Crick in 1953 which convinced 
biologists not only that genes are real molecules but also that 
they are constituted of nothing more mysterious than deoxyri-
bonucleic acid.”38 As Keller relates, 
[n]ot only did that structure provide a mechanism for the gene’s re-
markable capacity for self-replication—a mechanism that was stun-
ning in its very simplicity—but also, and at the same time, it provided 
an (equally simple) explanation for the stability of the gene—for the 
ostensibly miraculous fidelity with which it could be copied over so 
many generations. Complementary base-pairing could, at one fell 
swoop, do the work of both replication and conservation. . . . [A]n ac-
tual chemical substance—one already known to be a basic constituent 
of chromosomes—had been shown to have the necessary defining 
properties. Even before a mechanism was worked out by which the 
sequence of nucleotides in a DNA molecule could be translated into a 
sequence of amino acids in a protein molecule, confidence was wide-
spread that the material basis of genetics had finally been estab-
lished.39 
Watson and Crick demonstrated that: 
In the double helix, the two DNA chains are held together by hydro-
gen bonds . . . between pairs of bases on the opposing strands . . . . 
This base pairing is very specific: the purine adenine only base-pairs 
to the pyrimidine thymine, whereas the purine guanine only base-
pairs to the pyrimidine cytosine. In double-helical DNA, the number 
of A residues must be equal to the number of T residues, whereas the 
number of G and C residues must likewise be equal . . . . As a result, 
the sequence of the bases of the two chains of a given double helix 
have a complementary relationship, and the sequence of any DNA 
                                                          
 36. Oswald T. Avery et al., Studies on the Chemical Nature of the Sub-
stance Inducing Transformation of Pneumococcal Types, 79 J. EXPERIMENTAL 
MED. 137, 155 (1944). 
 37. A. D. Hershey and Martha Chase, Independent Functions of Viral Pro-
teins and Nucleic Acid in Growth of Bacteriophage, 36 J. GEN. PHYSIOLOGY 39 
(1952). 
 38. KELLER, supra note 21, at 3. 
 39. Id. at 23–25. 
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strand exactly defines that of its partner strand.40 
Studying the rII gene of the T4 bacteriophage, Seymour 
Benzer went beyond the discoveries of Watson and Crick, and 
“provided the crucial genetic evidence for the linearity of the in-
ternal structure of genes.”41 
Thus, the general materiality of the gene was comple-
mented by the additional conception of the gene as composed of 
a linear molecule comprised of a specific sequence of four deox-
yribonucleotides. In the less than fifty years that had passed 
since the word “gene” had been coined, the gene concept now 
included molecular materiality and a highly specific structure. 
This definitively physical concept allowed “the gene to become 
the foundational concept capable of unifying all of biology.”42 
Since the 1970s, it has been possible to determine the pre-
cise ordered sequence of nucleotides in a particular stretch of 
deoxyribonucleic acid of any type of organism, from eubacteria 
and archaea to plants and animals. Recombinant DNA technol-
ogy, by providing biologists with the ability to cut apart a DNA 
sequence at a specified locus, facilitated early sequencing ef-
forts.43 However, it was a pair of new sequencing techniques in 
the 1970’s that allowed DNA sequencing to commence on a 
grand scale. Almost simultaneously, two research groups de-
veloped methods by which one could determine the precise nuc-
leotide sequence of a fragment of DNA nucleotide base-pair by 
nucleotide base-pair. Both methods shared the same general 
approach: 
The underlying principle of DNA sequencing is based on the separa-
tion, by size, of nested sets of DNA molecules. Each of the DNA mole-
cules starts at a common 5’ end, and terminates at one of several al-
ternative 3’ endpoints. Members of any given set have a particular 
type of base at their 3’ ends. Thus, for one set, the molecules all end 
with a G, for another a C, for a third an A, and for the final set a T. 
Molecules within a given set (e.g., the G set) vary in length depending 
on where the particular G at their 3’ end lies in the sequence. Each 
fragment from this set therefore indicates where there is a G in the 
DNA molecule from which they were generated.44 
One group, led by Walter Gilbert and Allan Maxam, in-
vented a method of DNA sequencing later named “Maxam-
                                                          
 40. WATSON ET AL., supra note 30, at 22. 
 41. KELLER, supra note 21, at 52. 
 42. Id. at 3. 
 43. GRIFFITHS ET AL., INTRODUCTION TO GENETIC ANALYSIS 343-60 (2005). 
 44. WATSON ET AL., supra note 30, at 753. 
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Gilbert sequencing.”45 Maxam-Gilbert sequencing is based on 
radioactively labeling DNA molecules at their 5’ termini and 
then subjecting them “to four different regimens of chemical 
treatment that cause them to break preferentially at Gs, Cs, 
Ts, or As.”46 The other group, led by Frederick Sanger, devel-
oped the “chain-termination” method.47 In chain-termination 
sequencing, DNA polymerase is used to make a new copy of 
DNA from an existing DNA template, and modified 2’-,3’- di-
deoxynucleotides (ddNTPs) are incorporated into the new copy 
of DNA by DNA polymerase, preventing further elongation of 
the strand.48 
Gilbert and Sanger won the 1980 Nobel Prize in Chemistry 
“for their contributions concerning the determination of base 
sequences in nucleic acids.”49 Their methods of relatively rapid 
DNA sequencing spurred a rapid increase in the determination 
of the specific DNA sequences of many organisms, including 
humans. Rapid advancements in PCR, automated sequencers, 
and bioinformatics would later turn this rise into a flood, ulti-
mately leading to the sequencing of entire genomes.50 
D.  GENE AS INFORMATION 
As the material gene concept reached its apotheosis with 
the elucidation of the double helical structure of DNA, a quite 
different concept of the gene—as information—was simulta-
neously growing in importance among biologists. Early in the 
Twentieth Century, Archibald Garrod had proposed that “genes 
work by controlling the synthesis of specific enzymes.”51 In the 
early 1940s, George Beadle and Edward Tatum “used the fun-
gus Neurospora as a probe into the gene. Linking biochemical 
methods with the techniques of Mendelian genetics, the two re-
searchers demonstrated that one gene controlled a single chem-
ical reaction, which in turn was regulated by a specific en-
                                                          
 45. See Allan M. Maxam and Walter Gilbert, A New Method for Sequenc-
ing DNA, 74 PROC. NAT’L ACAD. SCI. U.S. 560 (1977). 
 46. WATSON ET AL., supra note 30, at 754. 
 47. See F. Sanger et al., DNA Sequencing with Chain-Terminating Inhibi-
tors, 74 PROC. NAT’L ACAD. SCI. U.S. 5463 (1977). 
 48. WATSON ET AL., supra note 30, at 754. 
 49. See Bo G. Malmstrom, Professor, Royal Academy of Sciences (1980), in 
NOBEL LECTURES: CHEMISTRY 377-432 (1980). 
 50. See, e.g., J. Craig Venter et al., The Sequence of the Human Genome, 
291 SCIENCE 1304 (2001); E. S. Lander et al., Initial Sequencing and Analysis 
of the Human Genome, 409 NATURE 860 (2001). 
 51. WATSON ET AL., supra note 30, at 19. 
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zyme . . . .”52 
By specifically linking the action of a single gene to the ac-
tion of a single enzyme, Beadle and Tatum confirmed Garrod’s 
“One Gene-One Enzyme Hypothesis.”53 Since all of the enzymes 
known at that time were proteins, “the key problem was the 
way genes participate in the synthesis of proteins.”54 Although 
there were numerous possible explanations for this phenome-
non, “[f]rom the very start of serious speculation, the simplest 
hypothesis was that genetic information within genes deter-
mines the order of the 20 different amino acids within the poly-
peptide chains of proteins.”55 
Soon after their discovery of the double helical structure of 
DNA, Watson and Crick were able to make informational infe-
rences from the double helix. As Keller relates: 
Watson and Crick published a second paper—on “Genetical Implica-
tions of the Structure of Deoxyribonucleic Acid”—whose main point 
was to argue that the structure of DNA show us [the mechanism by 
which DNA duplicates itself] . . . . Within such a framework, the one 
gene-one enzyme hypothesis took on a new kind of sense. Now it could 
be understood as suggesting a direct correspondence between the se-
quence of nucleotides in a gene and the sequence of amino acids in a 
protein . . . .56 
The information encoded by the sequence of deoxyribonuc-
leotides in a strand of DNA could be used to specify the synthe-
sis of a corresponding sequence of amino acids, yielding a pro-
tein. 
In 1957, Francis Crick proposed the “sequence hypothe-
sis.”57 “In its simplest form [Crick’s hypothesis] assumes that 
the specificity of a piece of nucleic acid is expressed solely by 
the sequence of its bases, and that this sequence is a (simple) 
code for the amino acid sequence of a particular protein.”58 Al-
though many additional details about protein synthesis are 
now known, this basic principle of information transfer from 
gene to protein is still considered sound. 
Despite elucidation of the general mechanism by which ge-
netic information translated into protein synthesis, the precise 
                                                          
 52. LILY E. KAY, WHO WROTE THE BOOK OF LIFE 52 (2000). 
 53. Id. 
 54. WATSON ET AL., supra note 30, at 19. 
 55. Id. 
 56. KELLER, supra note 21, at 51–52. 
 57. Id. at 52. 
 58. F. H. C. Crick, On Protein Synthesis, 12 SYMP. SOC’Y FOR 
EXPERIMENTAL BIOLOGY 138, 152 (1958). 
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code remained unknown. In the first definitive demonstration 
that information from nucleic acids corresponds specifically to 
protein sequence, Marshall Nirenberg and Heinrich Matthaei 
“observed in 1961 that the addition of the synthetic polynucleo-
tide poly U (UUUUU . . .) to a cell-free system capable of mak-
ing proteins leads to the synthesis of polypeptide chains con-
taining only the amino acid phenylalanine. The nucleotide 
groups UUU thus must specify phenylalanine.”59 
Over the next six years, Nirenberg, Matthaei, and other bi-
ologists raced to unravel all of the “words” in the “[genetic] 
code.”60 Accelerated by “fierce competition” among numerous 
research groups, “[b]y 1967 the [genetic] code was essentially 
completed; its momentous significance captured by the many 
scientific writings and media coverage which announced an im-
pending revolution in biology, both its epic promises and its pe-
rils.”61 
The influence of the “information gene concept” has re-
tained its salience right up until the present time. In addition 
to the widespread understanding of genes as material particles, 
“[t]he human genome is now generally viewed as an informa-
tion system and, more specifically, as a ‘Book of Life’ written in 
the language of DNA, or DNA code, to be read and edited.”62 
E.  GENE AS PROGRAM 
In an extension of the “information gene concept,” some bi-
ologists have suggested that genes are like programs that en-
code instructions that the cell must carry out. Even before the 
genetic code had been cracked, Francis Crick remarked that 
“DNA makes RNA, RNA makes protein, and proteins make 
us.”63 François Jacob and Jacques Monod proposed that “the 
genome contains not only a series of blue-prints, but a co-
ordinated program of protein synthesis and the means of con-
trolling its execution.”64 In late 1950s, Jacob and Monod had 
discovered that some genes encoded products that regulated 
the actions of other genes.65 They proposed the “operon model” 
                                                          
 59. WATSON ET AL., supra note 30, at 37. 
 60. KAY, supra note 52, at 330. 
 61. Id. 
 62. Id. at 1. 
 63. KELLER, supra note 21, at 54. 
 64. François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in 
the Synthesis of Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961). 
 65. WATSON ET AL., supra note 30, at 561. 
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to represent how such gene regulation might occur.66 The ope-
ron model spurred acceptance of the genetic program gene con-
cept by providing a specific example of such a genetic program. 
In his 1965 book, The Molecular Biology of Development, 
James Bonner envisioned a comprehensive “genetic program” 
to explain how genes built and maintained organisms.67 In this 
book, Bonner described a “master programme constituted in 
turn of a set of subprogrammes or subroutines.”68 He subdi-
vided the subroutine even further into “a list of cellular instruc-
tions or commands.”69 
Despite obvious similarities between computer programs 
and genetic programs, the latter do appear to possess impor-
tant differences from the former. In light of these differences, 
computers cannot take sole credit for the notion of a genetic program. 
Compelling as the analogy may be, equating the genetic material of 
an egg with the magnetic tape of a computer does not imply that that 
material encodes a program; it might, for example, just as well be 
thought of as encoding data to be processed by a program located 
elsewhere in the cell.70 
However, the program gene concept has been influential in 
suggesting that, just like computer software, a genetic program 
can confer qualities of consistency and predictability on an or-
ganism.71 Furthermore, if genes can be conceived of as genetic 
programs, then one may be able to “reprogram” organisms by 
modifying their genes. 
F.  THE GENE CONCEPT UNRAVELS 
The operon model proposed by Jacob and Monod signifi-
cantly complicated the understanding of what genes are. No 
longer did genes merely encode enzymes. They also encoded 
regulatory products. These products include “repressors,” “op-
erators,” “promoters,” “terminators,” “leaders,” and “activators,” 
each playing specific roles in the regulation of gene expres-
sion.72 This represented a dire threat to the “One Gene-One 
                                                          
 66. LEWIN, supra note 8. 
 67. See JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 6 
(1965). 
 68. Id. at 134. 
 69. KELLER, supra note 21, at 85–86. 
 70. Id. at 81. 
 71. As discussed below, organisms, in fact, tend to exhibit much less con-
sistency and predictability than the analogy with computer software would 
suggest. 
 72. WATSON ET AL., supra note 30, at 394–97, 547–49. 
TORRANCE LF CHECK.WEB (DO NOT DELETE) 3/9/2010  11:47 AM 
2010] GENE CONCEPTS 171 
Enzyme Hypothesis.” 
The DNA sequencing technologies developed in the 1970s 
revealed eukaryotic genes to be radically different in structure 
than had been assumed. Until the 1970s, most of the genes 
with known specific nucleotide sequences were derived from 
eubacteria or their viruses. For most of these organisms, “the 
coding sequence is contiguous: the codon for one amino acid is 
immediately adjacent to the codon for the next amino acid in 
the polypeptide chain.”73 However, the accumulation of DNA 
sequences from eukaryotic organisms demonstrated that euka-
ryotic genes almost always had more complex structures.74 
By the late 1970s, Richard Roberts and Philip Sharp had 
disproven the hypothesis that all genes were linear and conti-
nuous by demonstrating that quiescent, “nonexpressed” por-
tions of DNA (that is, “introns”) were situated in the midst of 
active, “expressed” portions of DNA (that is, “exons”) coding for 
polypeptides.75 In other words, “[m]any of the genes that code 
for proteins in higher organisms turn out not to be continuous 
but fragmented . . . .”76 Because of “this alternating pattern of 
exons and introns, genes bearing noncoding interruptions are 
often said to be ‘in pieces’ or ‘split’.”77 Thus, genes in eukaryotes 
depart significantly from earlier gene concepts that envisioned 
simple, linear contiguity. Rather, “[t]he highly interrupted 
structure of eukaryotic genes suggests a picture of the eukaryo-
tic genome as a sea of introns (mostly but not exclusively 
unique in sequence), in which islands of exons (sometimes very 
short) are strung out in individual archipelagoes that represent 
genes.”78 
The existence of introns and exons destroyed the universal 
applicability of the One Gene-One Enzyme Hypothesis. If genes 
are not linear and contiguous in sequence structure, but in-
stead fragmented, 
there is no strict one-to-one correspondence between the sequence of a 
gene and that of a protein it gives rise to. Thus the original RNA 
transcript directly transcribed from the gene (the messenger RNA, or 
mRNA) must be processed to remove these junk sequences before pro-
                                                          
 73. Id. at 415. 
 74. See id. 
 75. KELLER, supra note 21, at 59. 
 76. Id. 
 77. WATSON ET AL., supra note 30, at 415. 
 78. LEWIN, supra note 8, at 47. 
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tein synthesis can begin.79 
On average, a eukaryotic gene is split into four exons by 
three introns.80 There exists great variability in the number of 
introns a gene may have, “from one in the case of most intron-
containing yeast genes (and a few human genes), to 50 in the 
case of the chicken proα2 collagen gene, to as many as 363 in 
the case of the Titin gene of humans.”81 
Even genes divided by introns tend to be “transcribed into 
a single RNA copy of the entire gene.”82 Because “the protein-
synthesizing machinery of the cell . . . is equipped only to trans-
late mRNAs containing a contiguous stretch of codons,”83 the 
introns present in the initially transcribed “pre-mRNA” are fur-
ther processed by “RNA splicing.”84 The resulting mRNA is 
then ready to be translated into a polypeptide.85 However, even 
this scenario may be complicated further by “alternative splic-
ing,” wherein “mRNAs containing different selections of exons 
can be generated from a given pre-mRNA.”86 Through alterna-
tive splicing, “a gene can give rise to more than one polypeptide 
product,” each of which alternative polypeptides are called “iso-
forms.”87 Isoforms are the rule rather than the exception: “[i]t is 
estimated that up to 75% of the genes in the human genome 
are spliced in alternative ways to generate more than one iso-
form.”88 Furthermore, the numbers of possible isoforms from 
each individual gene can be staggering, ranging 
from two to hundreds or even thousands. For example, the Slo gene 
from rat, which encodes a potassium channel expressed in neurons, 
has the potential to encode 500 alternative versions of that product. 
And . . . one particular Drosophila gene can encode as many as 38,000 
possible products as a result of alternative splicing.”89 
Alternative splicing suggests a One Gene-Multiple Enzyme 
Hypothesis. 
There is even more complexity in genes beyond alternative 
splicing. Genes may also overlap one another. This may occur 
                                                          
 79. KELLER, supra note 21, at 60. 
 80. WATSON ET AL., supra note 30, at 415. 
 81. Id. at 415–16. 
 82. Id. at 416. 
 83. Id. at 417. 
 84. See id. 
 85. See id. 
 86. Id. 
 87. Id. 
 88. Id. 
 89. Id. 
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when “[t]he first half (or second half) of a gene is used indepen-
dently to specify a protein that represents the first (or second) 
half of the protein specified by the full gene.”90 Genes may also 
overlap in a more subtle manner when the same sequence of DNA is 
shared between two nonhomologous proteins. This situation arises 
when the same sequence of DNA is translated in more than one read-
ing frame. In cellular genes, a DNA sequence usually is read in only 
one of the three potential reading frames. In some viral and mito-
chondrial genes, however, there is an overlap between two adjacent 
genes that are read in different reading frames.91 
Genes have been discovered contained within larger 
genes,92 “nestled within the non-protein coding intron of anoth-
er [gene],”93 and in “countless other weird arrangements.”94 Re-
cent studies of “all the transcripts from ten chromosomes across 
eight human cell lines” have yielded a view of genes and their 
products characterized by “mind-boggling complexity.” 
Instead of discrete genes dutifully mass-producing identical RNA 
transcripts, a teeming mass of transcription converts many segments 
of the genome into multiple RNA ribbons of differing lengths. These 
ribbons can be generated from both strands of DNA, rather than just 
one as was conventionally thought. Some of these transcripts come 
from regions of DNA previously identified as holding protein-coding 
genes. But many do not.95 
In light of the evidence, a One Gene-Multiple Enzymes 
Hypothesis might be inadequate to describe what a gene is. 
Given the complexity discussed above, Benjamin Lewin, of 
Harvard University, has suggested an inversion of the Hypo-
thesis’ usual order; rather than One Gene-One Enzyme, he 
suggests One Enzyme-One Gene.96 
One of the leading genetics textbooks , GENES IX, by Ben-
jamin Lewin summarizes the complexities that increasingly 
call into question existing gene concepts in understated and 
somewhat enigmatic fashion: “[t]he concept of the gene has 
evolved significantly in the past several years. The question of 
what’s in a name is especially appropriate for the gene.”97 The 
                                                          
 90. LEWIN, supra note 8, at 45. 
 91. Id. 
 92. See Helen Pearson, What is a Gene?, 441 NATURE 399 (2006). 
 93. Id. at 401. 
 94. Id. at 399. 
 95. Id. 
 96. LEWIN, supra note 8, at 53 (using the most general term “polypeptide” 
instead of “enzyme”: “Instead of saying ‘one gene-one polypeptide,’ we may de-
scribe the relationship as ‘one polypeptide-one gene.’”). 
 97. Id. 
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name that has dominated discussions of units of heredity for a 
century—”gene”—has achieved vast influence both within biol-
ogy and in wider society. Yet, the scientific usefulness of the 
word “gene” is now in doubt among those most familiar with 
the evidence increasingly undermining the accuracy of gene 
concepts. Almost one-hundred years ago, the man who coined 
the term “gene,” Wilhelm Johannsen, justified his neologism by 
expressing his anxieties about previous descriptions of heredi-
tary units: “[i]t is a well established fact that language is not 
only our servant, when we wish to express—or even to con-
ceal—our thoughts, but that it may also be our master, overpo-
wering us by means of the notions attached to the current 
words.” 98 
After a century, Johannsen’s “very applicable little word”99 
may have graduated from servant to master and may now be 
“overpowering us by means of the notions attached to [it].”100 
One of the world’s preeminent geneticists, William Gelbart, has 
written that the gene might be “[a] concept past its time . . . . 
[U]nlike chromosomes, genes are not physical objects but are 
merely concepts that have acquired a great deal of baggage 
over the past decades.101 Though important in the development 
of genetics “we may well have come to the point where the use 
of the term ‘gene’ . . . might in fact be a hindrance to our under-
standing.”102 
Though the scientific justification of the “gene” has begun 
to wane, the power of what Keller terms “gene talk” has re-
mained strong. For the purposes of this article, “gene talk” re-
fers to the verbal invocation of the word “gene” or its attendant 
concepts. As Keller has suggested, gene talk has played key 
roles in the rise of biotechnology and the biotechnology indus-
try.103 And, one of the ways in which gene talk has been highly 
successful has been to secure property rights in genes through 
the patent system despite declining scientific certainty about 
what exactly a gene is. 
                                                          
 98. W. Johannsen, The Genotype Conception of Heredity, 45 THE AM. 
NATURALIST 129, 132 (1911). 
 99. Id. 
 100. Id. 
 101. William M. Gelbart, Databases in Genomic Research, 282 SCIENCE 
659, 660 (1998). 
 102. Id. 
 103. KELLER, supra note 21, at 10. 
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III.  GENE PATENTS 
A.  RECOMBINANT DNA 
In 1972, Dr. Ananda M. Chakrabarty, a staff biologist at 
General Electric Company, filed U.S. patent application serial 
number 05/260,563.104 This patent application claimed, among 
other inventions, a “bacterium from the genus Pseudomonas 
containing therein at least two stable energy-generating plas-
mids . . . .”105 In the wake of the watershed 1980 Supreme 
Court decision in Diamond v. Chakrabarty, allowing the pa-
tenting of recombinant eubacteria,106 this patent application is-
sued as United States Patent No. 4,259,444 (‘444 patent).107 
The ‘444 patent, which involves non-genomic “plasmids” con-
taining desired genes, 108 represents a key moment in the evolu-
tion of patentable subject matter. 
Stanley Cohen and Herbert Boyer, molecular biologists at 
Stanford University and the University of California San Fran-
cisco (“UCSF”), respectively, spent 1973 and 1974 developing a 
method for transferring DNA from one type of organism into 
the cells of a distinctly different type of organism.109 This 
marked the birth of the “recombinant DNA” revolution in biolo-
gy.110 In November of 1974, Stanford University and UCSF 
filed parent patent application 520,691 that ultimately ma-
tured into patent application 06/001,021, claiming recombinant 
DNA methods invented by Cohen and Boyer, and issued in 
1980 by the USPTO as U.S. Patent Number 4,237,224 (‘224 pa-
tent);111 the ‘224 patent claimed only recombinant DNA me-
thods, not DNA molecules or recombinant organisms them-
selves.112 By 1977, the human gene, somatostatin, had been 
expressed within the eubacterium, Escherichia coli.113 Recom-
                                                          
 104. U.S Patent No. 4,259,444 (filed June 7, 1972). 
 105. Id. at col.16 l.23–25. 
 106. See Diamond v. Chakrabarty, 447 U.S. 303, 318 (1980). 
 107. ‘444 Patent. 
 108. See id. 
 109. Sally Smith Hughes, Making Dollars Out of DNA: The First Major Pa-
tent in Biotechnology and the Commercialization of Molecular Biology, 92 ISIS 
541, 541 (2001). 
 110. Id. at 542. 
 111. Id. 
 112. U.S. Patent No. 4,237,224 col. 17 l.4–31(filed Jan. 4, 1979). Note that 
all fourteen claims begin with the words “A method.” 
 113. See Keiichi Itakura et al., Expression in Escherischia coli of a Chemi-
cally Synthesized Gene for the Hormone Somatostatin, 198 SCIENCE 1056, 
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binant DNA technology offered “a simple method for isolating 
and amplifying any gene or DNA segment and moving it with 
controlled precision, allowing analysis of gene structure and 
function in simple and complex organisms.”114 When coupled 
with the relatively rapid DNA sequencing methods developed 
in the mid-1970s, modern biotechnology had been born.115 
B.  PATENTS ON GENES 
As the 1970’s dawned, biologists, and the institutions that 
employed them, began securing significant numbers of patents 
claiming the complex organic molecules of life. In 1971, U.S. 
Patent Numbers 3,607,370116 and 3,619,206117 issued, claiming 
“polypeptide” and “protein” per se, respectively. Earlier, patents 
had issued claiming methods involving polypeptides and pro-
teins. In 1972, the first claim to a “peptide” per se appeared in 
U.S. Patent Number 3,645,689.118 By 1973, “DNA” had been in-
cluded as an element of a patented claim.119 
The term “gene” first appeared as a claim element in U.S. 
Patent No. 3,710,511.120 By 1978, U.S. Patent Number 
4,116,770 had issued, and its claims 10, 11, and 12 were di-
rected to phenotypic traits expressed by specific “genes.”121 Fi-
nally, in 1982 U.S. Patent No. 4,363,877 (“the ‘877 patent”) is-
sued, and included independent claims 1 and 4, which were 
directed to “recombinant DNA transfer vector[s]” comprising 
specified nucleotide sequences of codons for “human chorionic 
somatomammotropin” and “the growth hormone of an animal 
species,” respectively.122 This was the first “gene” patent, claim-
                                                          
1056–63 (1977). 
 114. Hughes, supra note 109, at 541. 
 115. See discussion supra Part II.F. 
 116. Entitled “Pressure-Sensitive Adhesive Tape Comprising Gluten Hy-
drolypate Derivatives.” 
 117. Entitled “Modified Proteins.” 
 118. See U.S. Patent No. 3,645,689 (filed Apr. 9, 1970) (Entitled “Method 
and Apparatus for Analyzing Proteins”). 
 119. See U.S. Patent No. 3,755,086 (filed Feb. 9, 1971) (Entitled “Diagnostic 
Method Utilizing Synthetic Deoxyrilionucleotide Oligomer Template”). 
 120. See U.S. Patent No. 3,710,511 (filed Apr. 21 1971) (Entitled “Proce-
dures for Use of Genic Male Sterility in Production of Commercial Hybrid Ma-
ize”). 
 121. See U.S. Patent No. 4,116,770 (filed Feb. 27, 1975). 
 122. See U.S. Patent No. 4,363,877 (filed Apr. 19, 1978) (Entitled “Recom-
binant DNA Transfer Vectors”). 
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ing genes per se.123 Although the claims of the ‘877 patent did 
not specifically recite the word “gene,” the specification’s 
“SUMMARY OF INVENTION” did identify “genes coding for 
RGH, the major portion of HCS and the major portion of HGH, 
respectively.”124 Oddly, this first gene patent largely failed to 
define a gene. The closest the ’877 patent’s specification gets to 
such a definition is the following passage: “isolating the mRNA 
which contains the nucleotide sequence coding for the amino 
acid sequence of a particular protein is equivalent to the isola-
tion of the same sequence, or gene, from the DNA itself.”125 In 
other words, the ‘877 patent equates a gene with the nucleotide 
sequence of an mRNA transcript; by implication, a gene is 
simply a nucleotide sequence that produces an mRNA. 
Patents and patent applications claiming genes both in-
creased rapidly after the Diamond v. Chakrabarty decision in 
1980. Figure 1 shows annual patent application filings with 
“gene” in at least one claim during the period from 1971 to 
2007. Such filings rose from just above zero in 1977 to more 
than 100 in 1984, more than 500 in 1993, almost 1000 in 1994, 
to a peak of over 1600 filed in 1995 alone. While filings re-
mained at least—or extremely close to—1000 per year from 
1994 until 2002, thereafter filings of such patent applications 
declined rapidly to well below 500 through 2007.126 By way of 
comparison, Figure 1 also shows that annual patent filings 
with “DNA” or “nucleotide sequence” in at least one claim fol-
low the same trajectory as do those with “gene.” 
 
 
 
 
 
 
 
 
 
                                                          
 123. Leslie Gladstone Restaino & Theresa Takeuchi, Gene Patents and 
Global Competition Issues, 26 GENETIC ENGINEERING AND BIOTECHNOLOGY 
NEWS 10, 10 (2006). 
 124. ‘877 Patent, at col.8 l.7–9. 
 125. Id. at col.5 l.35–40 (emphasis added). 
 126. These data includes a lag-time of approximately 18 months, reflecting 
the rolling publication window of 18 months from earliest priority date. 
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Figure 2 shows annual patent issuances with “gene” in at 
least one claim during the period from 1971 to 2007. Such fil-
ings rose from just above zero in 1981 to more than 100 in 
1988, more than 500 in 1996, more than 1300 in 1998, to a 
peak of almost 1500 in 1999. From 1998 to 2007, patent is-
suances have remained above 1000 per year in all but two 
years, and there has been only a relatively gradual decline in 
issuances from the peak year of 1999. By way of comparison, 
Figure 2 also shows that annual issuances of patents with 
“DNA” in at least one claim follow the same trajectory as do 
those with “gene.” 
 
 
 
 
 
 
 
 
C.  GENES IN PATENTS 
Neither patents nor patent litigation tend to spend much 
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effort attempting to define what a gene is.127 Although many 
thousands of patent applications have employed the words 
“gene” or “genes” within their claims, and a significant fraction 
of these patent applications have issued as United States pa-
tents, seldom do patent applicants trouble themselves with de-
fining these terms in their specifications. For example, of the 
more than 15,000 issued U.S. patents that include the term 
“gene” in their claims, only sixteen include the phrase “a gene 
is defined as,” only seventeen include the phrase “genes are de-
fined as,” only ten include the phrase “definition of a gene,” and 
only four include the phrase “definition of genes.”128 
Similarly, of a group of fifteen federal court opinions that 
discuss gene definitions,129 only two, Amgen, Incorporated v. 
Chugai Pharmaceutical Company, 130 and Carnegie Mellon 
University v. Hoffman-La Roche Incorporated,131 actually pro-
vide a definition of a gene.132 However, the Amgen definition 
                                                          
 127. A review of the first 500 search results of patents in “Google Patent 
Search” reveals that only about 20% of the resulting patents attempt to define 
“gene.” Almost all of these definitions are highly simplistic in nature, and none 
of them seriously reflects the scientific complexity that has surrounded genes 
over the last several decades. 
 128. These results are based on searches of these exact phrases in the 
Google Patent Search database of all “Issued Patents” on April 9, 2008. 
 129. Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1232 (Fed. Cir. 
2008); Mycogen Plant Sci., Inc. v. Monsanto Co., 91 Fed. Appx. 666, 667 (Fed. 
Cir. 2004); Genzyme Corp. v. Transkaryotic Therapies, Inc., 346 F.3d 1094, 
1105 (Fed. Cir. 2003); Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316 
(Fed. Cir. 2002); Mycogen Plant Sci., Inc. v. Monsanto Co., 252 F.3d 1306, 
1319 (Fed. Cir. 2001), vacated, 535 U.S. 1109 (2002); Hitzeman v. Rutter, 243 
F.3d 1345, 1357 (Fed. Cir. 2001); In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir. 
1995); Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 
1991); In re Merat, 519 F.2d 1390, 1392 (C.C.P.A. 1975); Carnegie Mellon Un-
iv. v. Hoffman-La Roche, Inc., No. C 95-3524 SI, No. C 01-0415 SI, 2007 U.S. 
Dist. LEXIS 20386, at *8 (N.D. Cal. Mar. 22, 2007); Carnegie Mellon Univ. v. 
Hoffman La Roche, Inc., 148 F. Supp. 2d 1004, 1013 (N.D. Cal. 2001), aff’d, 
541 F.3d 1115 (Fed. Cir. 2008); E.I. Du Pont de Nemours & Co. v. Okuley, No. 
C2-97-1205, 2000 U.S. Dist. LEXIS 21385, at *57 (S.D. Ohio Dec. 21, 2000), 
aff’d, 344 F.3d 578 (6th Cir. 2003); Trs. of Columbia Univ. v. Roche Diagnos-
tics GmbH, 126 F. Supp. 2d 16, 21 (D. Mass. 2000); Monsanto Co. v. Mycogen 
Plant Sci., Inc., 61 F. Supp. 2d 133, 155 (D. Del. 1999); Genentech, Inc. v. Boe-
hringer Mannheim GmbH, 989 F. Supp. 359, 364-65 (D. Mass. 1997). These 
opinions were the result of a search (“gene” w/3 defin!) of the LexisNexis® 
“Federal Court Cases, Combined” database. 
 130. Amgen, 927 F.2d at 1206. 
 131. Carnegie Mellon, 2007 U.S. Dist. LEXIS 20386, at *8. 
 132. Note that Carnegie Mellon, 148 F. Supp. 2d at 1013, simply cites Am-
gen for how not to define a gene. 
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(“A gene is a chemical compound, albeit a complex one.”)133 is so 
general as to approach the tautological, and the Carnegie Mel-
lon University definition (“A gene may be defined as a region of 
DNA that contains information that a cell uses to make a par-
ticular protein.”)134 is scientifically inaccurate (e.g., because it 
ignores introns), vague, and uninformative. 
In 2006, an article provocatively entitled What is a Gene?, 
was published in Nature,135 a journal many—perhaps even 
most—scientists would acknowledge as the most prestigious 
and influential scientific journal in the world. In this article, 
Helen Pearson describes widespread disagreement and confu-
sion among biologists about the meaning of the word “gene.”136 
She quotes William Gelbart, a famous and well-published gene-
ticist at Harvard University, as saying, “I find it sometimes 
very difficult to tell what someone means when they talk about 
genes because we don’t share the same definition.”137 Despite 
the fact that What is a Gene? was published in such a promi-
nent journal, and has undoubtedly been read by many genetic-
ists, this article about the uncertainty surrounding gene con-
cepts has been cited only a single time by a U.S. patent or 
patent application.138 This application cites to What is a Gene? 
and states that “[w]hile the definition of a ‘gene’ is an increa-
singly complex issue, what is of immediate interest for drug 
discovery and development is a catalogue of those genes that 
encode functional, expressed proteins.”139 In other words, de-
spite difficulties in describing what a gene actually is, the over-
riding priority for “drug discovery and development”140 should 
be to “catalogue”141 the useful products of genes rather than the 
genes that encode those useful products. This patent applica-
tion may reflect a larger manifesto of biotechnology: it is more 
important to locate potentially useful products of genes than to 
know the characteristics of the genes that encode them. Applied 
                                                          
 133. Amgen, 927 F.2d at 1206. 
 134. Carnegie Mellon, 2007 U.S. Dist. LEXIS 20386, at *8. 
 135. Pearson, supra note 92. 
 136. Id. at 399. 
 137. Id. at 401. 
 138. U.S. Patent Application Publication Number US 2007/0166765 A1, at 
[0358] (filed Jan. 7, 2007) (the publication for U.S. Patent Application Serial 
Number 11/653,771 (“‘771 application”)). 
 139. Id. (internal citation omitted). 
 140. Id. 
 141. Id. 
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to gene patents, this manifesto would emphasize the descrip-
tion of gene function over the description of gene structure. Pa-
tent law, however, requires description of structure,142 and dis-
allows “functional claiming” of biotechnological inventions.143 
IV.  GENE TALK 
A.  THE BIOTECHNOLOGY INDUSTRY 
The biotechnology industry144 is substantially based on 
geneand gene-based inventions. The products of that in-
dustry are made possible by technologies that allow genes to be 
located within the genome, sequenced deoxyribonucleotide by 
deoxyribonucleotide, isolated out of their original genomic loci 
and spliced into brand new loci, and expressed more or less 
than usual. The biotechnology industry relies on the availabili-
ty of patent protection to appropriate the economic value of 
genes. Patents and patent applications allow biotechnology 
companies to attract investments and other sources of funding 
and to protect their own immense investments in discovering, 
developing, securing regulatory approval, and successfully 
marketing their products. Consequently, the biotechnology in-
dustry also has strong incentives to maintain the patentability 
of gene inventions. As Sheila Jasanoff has described in her 
book, Designs on Nature, 
[e]specially in the United States, patents played a foundational role in 
the development of the biotechnology industry at several levels. First, 
the extension of patents to the life sciences created new classes of 
property rights in things that were previously outside the realm of 
what could be owned, or even thought of as subject to ownership 
claims. As a result, these objects became commodities that could have 
value, be exchanged, circulate in markets, and foster productivity. 
Second, much of the early development of biotechnology occurred be-
fore there were any marketable products, and patents were the only 
evidence for eager venture capitalists that there might be something 
                                                          
 142. Medical Instrumentation and Diagnostics Corp. v. Elekta AB, 344 
F.3d 1205, 1211 (Fed. Cir. 2003) (“If the specification is not clear as to the 
structure that the patentee intends to correspond to the claimed function, then 
the patentee has not paid that price [the quid pro quo of disclosing structure 
corresponding to function] but is rather attempting to claim in functional 
terms unbounded by any reference to structure in the specification. Such is 
impermissible under the [Patent] statute.”) 
 143. See, e.g., University of Rochester v. G. D. Searle, Inc., 249 F. Supp. 2d 
216236 (W.D.N.Y. 2003). 
 144. Herein, the biotechnology industry is assumed also to include phar-
maceutical companies significantly dependent on biotechnologies. 
TORRANCE LF CHECK.WEB (DO NOT DELETE) 3/9/2010  11:47 AM 
182 MINN. J. L. SCI. & TECH. [Vol. 11:1 
of future value to justify present investment. Third, patents provided 
some assurance to jittery investors that they would not be mired in 
endless legal wrangling if commercially useful products ever came on 
line. Fourth, patents proved to be a way of sorting out the competing 
claims to participants in an increasingly complex web of invention 
that linked together the disparate interests of patients, research sub-
jects, farmers, academic researchers, universities, start-up firms, gov-
ernment, and industry.145 
The patent system offers federal legal protection for gene 
inventions, offering powerful rights to exclude others from 
making, using, offering to sell, or selling patented genes within 
the United States, or importing patented genes into the United 
States.146 
Patent protection for genes and their products is a keys-
tone asset of pharmaceutical and biotechnology companies, as 
well as a valuable source of revenue for universities and gov-
ernment research institutes. In fact, some have argued that the 
main product of the biotechnology industry, which, as a whole, 
has yet to turn a profit, is not genes per se, or their uses or 
products, but patents claiming genes or the uses or products 
thereof.147 Availability of patent protection for genes has gener-
ally been assumed to promote innovation in biotechnology,148 
spurring the discovery and elucidation of relatively more new 
genes, while simultaneously limiting others’ access to those 
same new genes.149 
B.  THE RISE OF GENE TALK 
Given the importance of genes to the biotechnology indus-
                                                          
 145. SHEILA JASANOFF, DESIGNS ON NATURE: SCIENCE AND DEMOCRACY IN 
EUROPE AND THE UNITED STATES 203–04 (2005) (internal citations omitted). 
 146. 35 U.S.C. § 271(a) (2006). 
 147. See, e.g., John M. Golden, Biotechnology, Technology Policy, and Pa-
tentability: Natural Products and Invention in the American System, 50 
EMORY L.J. 101, 105-06 (2001). 
 148. In their recent study of the role that the patent system plays in spur-
ring innovation, James Bessen and Michael J. Meurer suggest the patent sys-
tem may indeed promote innovation in the pharmaceutical/biotechnology in-
dustry. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE—HOW 
JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 85–88 (2008). 
As Bessen and Meurer have stated, “The evidence certainly is consistent with 
the notion that patents encourage American pharmaceutical R & D.” James 
Bessen & Michael J. Meurer, Do Patents Stimulate R & D Investment and 
Promote Growth?, PATENTLY-O BLOG (Mar. 13, 2008, 4:17 AM), 
http://www.patentlyo.com/patent/2008/03/do-patents-stim.html. 
 149. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innova-
tion? The Anticommons in Biomedical Research, 280 SCIENCE 698, 699 (1998). 
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try, threats to the coherence or accuracy of gene concepts, if 
they were to undermine the prospect of receiving gene patents, 
could threaten the biotechnology industry itself. Until recently, 
the widespread perception of such threats has appeared to be 
minimal. According to Keller, 
[f]or almost fifty years, we lulled ourselves into believing that, in dis-
covering the molecular basis of genetic information, we had found the 
“secret of life”; we were confident that if we could only decode the 
message in DNA’s sequence of nucleotides, we would understand the 
“program” that makes an organism what it is. And we marveled at 
how simple the answer seemed to be.150 
As Francis Crick so succinctly put it, “DNA makes RNA, 
RNA makes protein, and proteins make us.”151 
In fact, genes have been a scientific and cultural success 
story to rival any in the history of science. As Keller suggests, 
[t]oday, the prominence of genes in both the general media and the 
scientific press suggests that in this new science of genomics, twen-
tieth-century genetics has achieved its apotheosis. Yet, the very suc-
cesses that have so stirred our imagination have also radically un-
dermined their core driving concept, the concept of the gene.152 
Keller considers the gene to be a scientific concept whose 
days of influence may be numbered, because 
even though the message has yet to reach the popular press, to an in-
creasingly large number of workers at the forefront of contemporary 
research, it seems evident that the primacy of the gene as the core 
explanatory concept of biological structure and function is more a fea-
ture of the twentieth century than it will be of the twenty-first. What 
will take its place? Indeed, we might ask, will biology ever again be 
able to offer an explanatory framework of comparable simplicity and 
allure?153 
However, Keller has identified several important roles that 
gene talk serves in maintaining belief in the fiction of the 
“gene” even in the face of mounting scientific evidence to the 
contrary: 
Paramount among these is the convenience of gene talk as an opera-
tional shorthand for scientists working in specific experimental con-
texts. Furthermore, gene talk identifies concrete levers or handles for 
effecting specific kinds of change. And finally, gene talk is an undeni-
ably powerful tool of persuasion, useful not only in promoting re-
search agendas and securing funding but also (perhaps especially) in 
marketing the products of a rapidly expanding biotech industry.154 
                                                          
 150. KELLER, supra note 21, at 7. 
 151. Id. at 54. 
 152. Id. at 5. 
 153. Id. at 9. 
 154. Id. at 10. 
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C.  GENE TALK AND GENE PATENTS 
Gene talk by the biology community to constituencies out-
side that community rarely addresses the complexities and un-
certainties surrounding genes. One explanation for such omis-
sion is the perceived need to simplify complex scientific 
concepts to communicate effectively to constituencies lacking 
scientific knowledge and training. The lack of consensus within 
the biology community regarding gene concepts may constrain 
what information can accurately and effectively be communi-
cated. An alternative explanation is that the biologists circum-
scribe their disagreements about gene concepts to occur only 
within their own community, while they maintain a normative 
silence on those same disagreements when addressing outside 
constituencies, to protect their access to valuable gene patents. 
In other words, the biology community tells a story of complexi-
ty internally, whereas it tells a different, much simpler, story 
externally. Such epistemic compartmentalization would help 
the biology community to achieve two important goals simulta-
neously: (1) relatively free internal scientific enquiry about 
genes to foster scientific advances and (2) minimization of ex-
ternal leakage of internal scientific disputes to protect contin-
ued access to potentially valuable gene patents. In fact, goal (2), 
by proprietizing and monetizing the fruits of goal (1) might be 
viewed by at least some in the biology community as one me-
thod of promoting goal (1). 
Keller’s research supports the notion that those with 
strong incentives to sustain the concept of the “gene” may en-
gage in gene talk with the aim of sustaining the vitality of what 
many geneticists now consider a moribund idea: 
Throughout the many variations and transformations that we have 
seen in the concept of the gene over the course of its lifetime, it had 
always been possible in the past to contain whatever definitional dif-
ficulties had plagued that concept; one might even say that it had 
been functional, both experimentally and professionally, to keep its 
internal incoherence under wraps.155 
In fact, Keller has expressly questioned whether the biolo-
gy community has attempted to obscure the failure of the gene 
concept from constituencies outside biology community. As she 
has stated, “It’s been a growing conviction of mine that biolo-
gists have a whole other way of talking to each other in the lab 
than they do to the public.”156 
                                                          
 155. Id. at 69–70. 
 156. Brown, supra note 2. 
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How the biology community portrays genes to the public 
may have profound effects on what society believes about 
genes. To understand how scientific concepts or technologies af-
fect societies, Jasanoff has stressed the importance of also 
“ask[ing] how societies produce authoritative knowledge and 
functioning technological artifacts.”157 By considering the latter 
question, 
it has been possible to demonstrate that the products of the sciences, 
both cognitive and material, embody beliefs not only about how the 
world is, but also how it ought to be. . . . The apparent firmness of the 
devices with which we make sense of our existence . . . is maintained 
through more or less purposive action by identifiable actors. Accor-
dingly, to understand how . . . natural entities such as “the gene” 
function in the world, one has to ask how diverse actors use and un-
derstand the concept, how it is articulated through formal and infor-
mal practices, where and by whom it is contested, and how it reas-
serts itself in the face of challenges to its integrity or meaning.158 
Gene talk fits well into this conceptual framework. 
Biology is a branch of science devoted to studying especial-
ly complex structures and processes. Perhaps due in part to 
this complexity, the biology community has achieved consider-
able success in preventing the gene concept from becoming ex-
ternally contested. While gene concepts are vigorously con-
tested within the biology community, 159 the bar for legitimacy 
and authority in this debate is exceedingly high: doctoral de-
grees, professorships, publication in peer reviewed journals, 
memberships in exclusive learned societies, and perhaps even 
gene patent inventorship are required. Indeed, this high entry 
barrier largely excludes those with lesser credentials from 
access to these internal gene debates. Members of the biology 
community already in possession of such credentials tend to 
command a privileged position in external discourse about 
genes. Their opinions about genes tend to be considered more 
authoritative by constituencies beyond the biology community 
than are opinions expressed by less credentialed actors outside 
that community. Although the biology community understands 
that there remain great uncertainties regarding gene concepts, 
the value its members place on the prospect of receiving gene 
patents, and the monetary rewards that may accompany them, 
may create significant disincentives to expressing to those out-
side the biology community—including the USPTO—how com-
                                                          
 157. JASANOFF, supra note 145, at 19. 
 158. Id. 
 159. See, e.g., Pearson, supra note 92 at 399–401. 
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plex, complicated, and uncertain gene concepts actually are. 
Consequently, the biology community contests gene concepts 
internally, while simultaneously portraying the gene to other 
constituencies—including the USPTO—as relatively predicta-
ble and straightforward. Thus, adapting the Jasanoff rubric, 
the biology community may be able to maintain “the apparent 
firmness of the [gene] device[]” by its “purposive action” of pro-
moting a simple and predictable gene to outside constituen-
cies,160 in particular the USPTO. 
Significant incentives exist for a patent applicant not to 
acknowledge uncertainty or incoherence in the gene concept be-
cause such acknowledgment risks lowering the probability that 
the USPTO will grant the applicant’s patent, or exposing the 
patent later to invalidity challenges in litigation. Widespread 
acknowledgment of this uncertainty or incoherence would have 
the potential to undermine the market value of the biotechnol-
ogy industry, as well as to impoverish other beneficiaries of 
gene patents, such as investors, universities, and patent attor-
neys and agents. Patent applicants have an affirmative obliga-
tion to disclose certain information to the USPTO.161 Such 
“[i]nformation must be disclosed [by a patent applicant] when it 
is material to patentability [of a patent application].”162 The re-
luctance to admit uncertainties in gene concepts certainly vi-
olates the spirit of this affirmative obligation of disclosure; and, 
depending upon the context, it could also violate the letter of 
this obligation. If a patent applicant claiming a gene or gene-
related invention were aware of a prior art reference whose 
teaching cast into doubt the validity of the claimed invention or 
the sufficiency of the disclosure supporting the claimed inven-
tion, the patent applicant would be obligated to provide that 
prior art reference to the USPTO even if this lowered the prob-
ability of the claim ever issuing. Much prior art exists detailing 
the many uncertainties that surround genes, gene structures, 
and gene functions.163 Yet, such prior art is rarely included in 
the patent specifications of gene patents. Even in litigation, 
gene patents rarely fact the issue of gene concepts in more than 
                                                          
 160. JASANOFF, supra note 145, at 19. 
 161. 37 C.F.R. §1.56 (2008). 
 162. Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d 
1253, 1257 (Fed. Cir. 1997). 
 163. See, e.g., Pearson, supra note 92, at 399–401 (citing studies and the 
general consensus within the biology community that our understanding of 
‘gene’ is not completely accurate). 
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a cursory manner, despite the fact that uncertainty about gene 
concepts may have the potential to cast doubt on the validity of 
many gene patents. Gene concepts rarely arise in patent litiga-
tion, which may be evidence that gene talk has successfully in-
fluenced even the judicial process.164 
Jasanoff has suggested that the economic success, and 
even existence, of the biotechnology industry is undergirded by 
the availability of gene patents.”165 In her view, the patent sys-
tem serves a variety of functions as it mediates between “inven-
tors” of genes (and other biotechnological inventions) and mar-
kets capable of imbuing genes with economic value.166 Patents 
play many valuable roles in support of the biotechnology indus-
try, and confer considerable economic value on the beneficiaries 
of gene, and gene-based, inventions. Consequently, it would be 
rational for beneficiaries of the patent system to support the 
continuing availability of patent protection for gene, and gene-
based, inventions by engaging in gene talk. 
The acceptance by the patent system of a gene concept that 
is inaccurately simplified and predictable might even influence 
gene concepts in the reverse direction as well. The “patent gene 
concept” might influence biologists to describe, and even think 
about, genes in a manner consistent with patent availability. 
The prospect of a patent-derived windfall is ever-present 
among biologists, especially those involved in medical research. 
Although there may be other rewards for pursuing biology, 
such as Mertonian norms of free enquiry and free exchange of 
ideas, prestige, intellectual challenge, and a sense of impor-
tance to society, the possibility of winning the patent-lottery by 
patenting a lucrative gene may be a significant incentive not to 
undermine the patentability of genes, even at the expense of 
debate within the biology community. The biology community 
may thus possess an incentive to privilege a simple and un-
complicated gene concept not only to the outside world, but also 
within its own intellectual community, instead of promoting 
debate about competing gene concepts, or what, if anything, a 
gene actually is. In short, the “patent gene concept” may also 
influence how biologists portray and conceive of genes, encour-
aging them, for example, to emphasize the certainty of know-
ledge about the gene over the uncertainty. 
                                                          
 164. See supra note 129 and related discussion. 
 165. JASANOFF, supra note 145, at 203–04. 
 166. Id. 
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Biologists and the biotechnology industry may have good 
reason to avoid publicly trumpeting the failure of the gene con-
cept in public. Although the USPTO does consider genes per 
seat least when isolated or purifiedto be patentable subject 
matter, it has excluded fragments of genes from patentabili-
ty.167 In the early 1990s, the USPTO began to reject patent ap-
plications claiming expressed sequence tags (“ESTs”).168 
As defined by the Court of Appeals for the Federal Circuit, 
“[a]n EST is a short nucleotide sequence that represents a 
fragment of a cDNA clone.”169 In In re Fisher, the Court re-
jected the patentability of such gene fragments as lacking utili-
ty (and enablement) “because Fisher does not identify the func-
tion for the underlying protein-encoding genes.”170 If claims to 
ESTs tend to lack utility and enablement, then so might claims 
to genes composed of multiple gene fragments. Gene talk can 
contribute to the solution to this problem by avoiding discus-
sion of the complexities of gene structure, and focusing, in-
stead, on a simple and comfortable, though inaccurate, gene de-
finition. 
An influential gene patent case, Amgen v. Chugai Pharma-
ceutical Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991), may provide 
additional incentive for biologists and those in the biotechnolo-
gy industry to engage in protective gene talk. Amgen mandates 
a significant level of detailed knowledge about a gene before a 
patent claiming the gene can be granted: 
A gene is a chemical compound, albeit a complex one, and it is well es-
tablished in our law that conception of a chemical compound requires 
that the inventor be able to define it so as to distinguish it from other 
materials, and to describe how to obtain it. Conception does not occur 
unless one has a mental picture of the structure of the chemical, or is 
able to define it by its method of preparation, its physical or chemical 
properties, or whatever characteristics sufficiently distinguish it. It is 
not sufficient to define it solely by its principal biological property, 
e.g., encoding human erythropoietin, because an alleged conception 
having no more specificity than that is simply a wish to know the 
identity of any material with that biological property. We hold that 
when an inventor is unable to envision the detailed constitution of a 
gene so as to distinguish it from other materials, as well as a method 
for obtaining it, conception has not been achieved until reduction to 
                                                          
 167. In re Fisher, 421 F.3d 1365, 1373 (Fed. Cir. 2005). 
 168. See Leslie Roberts, Gene Patents: Rumors Fly over Rejection of NIH 
Claim, 257 SCIENCE 1855, 1855 (1992) (noting that the USPTO rejected NIH’s 
EST application in an office action dated August 20, 1992). 
 169. In re Fisher, 421 F.3d at 1367. 
 170. Id at 1376. 
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practice has occurred, i.e., until after the gene has been isolated.171 
Without gene talk, the standard of description mandated 
by Amgen might be insurmountable for many gene patent ap-
plicants. In light of the current understanding of how difficult 
it is to define a eukaryotic gene, the standard articulated by the 
court may be unreachable. Patent applicants might be able to 
isolate mRNA molecules and then reverse transcribe them into 
cDNAs. However, successfully envisioning “the detailed consti-
tution of a gene” has the potential to become an ever more diffi-
cult challenge if gene concepts continue to decay and degrade. 
Again, gene talk may provide a degree of prophylaxis. 
For example, as a consequence of how genes tend to be 
claimed in patents, the perception may already have grown 
among biologists that “genes” are synonymous with nucleic acid 
sequences. The patenting of gene-associated DNA sequences 
may have altered the perception among both biologists and the 
public regarding what is, and is not, a gene. Gene talk may 
even create an incentive among biologists for duplicity; it may 
encourage them to depict genes inconsistently in scientific pub-
lications and patent applications. Differing portrayals of the 
same gene in related publications and patent applications 
might encourage patent examiners to doubt the sincerity of 
gene definitions in patent applications. In addition, such beha-
vior might qualify as inequitable conduct, rendering relevant 
patents unenforceable.172 
Not every aspect of genes has been beyond public conten-
tion. Indeed, the biology community appears to have failed to 
persuade the public that patenting genes is socially valuable; in 
this sense, the gene concept promoted by the biology communi-
ty has failed to become a generally authoritative view among 
constituencies outside the biology community. As Jasanoff de-
scribes, 
[t]he political controversies surrounding the patenting of DNA se-
quences in the United States raises [sic] an interesting puzzle. Why 
did concern surface with regard to these products when equally signif-
icant enlargements in the scope of patentability—from nonliving to 
living matter and from lower to higher organisms—had garnered 
nothing but praise from U.S. scientists? We must conclude that this 
                                                          
 171. Amgen, 927 F.2d at 1206 (citation omitted). 
 172. Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d 
1253, 1256 (Fed. Cir. 1997) (“Inequitable conduct resides in the failure to dis-
close material information with an intent to deceive or mislead the PTO.”) (cit-
ing J.P. Stevens & Co. v. Lex Tex, Ltd., 747 F.2d 1553, 1559–60 (Fed. Cir. 
1984)). 
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step more than any previous one created competitive divisions within 
the very heart of biotechnological research and development.173 
Yet, even where the gene patent issue has become conten-
tious, it has been concerns over ethics, morality, and free access 
to genes for research purposes—not any perceived ambiguities 
or complexities of the gene concept—that have animated the 
debate. For example, in the vigorous debate surrounding pro-
posed H.R. 977 (“A bill to amend title 35, United States Code, 
to prohibit the patenting of human genetic material”), little 
support exists in the legislative history for the proposition that 
genes should be unpatentable because the gene concept is inac-
curate.174 Despite the influence public acknowledgement of un-
certainties surrounding the gene concept might have had on 
the debate, it is possible that gene talk successfully influenced 
members of the biology community not to share their internal 
controversies and debates with outside constituencies that 
could have interfered with the prospect of receiving valuable 
gene patents. 
V.  CONCLUSION 
The concept of the gene has evolved rapidly over the last 
one-hundred years. At various times, gene concepts have em-
phasized materiality, agency, reproductive capacity, and the 
ability to direct cells and organisms.175 In the words of Erwin 
Schrodinger, the gene is “lawcode and executive power—
architect’s plan and builder’s craft—in one.”176 
Methods of isolating, manipulating, sequencing, and con-
trolling genes formed the foundations of the biotechnology in-
                                                          
 173. JASANOFF, supra note 145, at 224. 
 174. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (2007); 
see, e.g., Legislation to Prohibit Human Genetic Patents Proposed in U.S., PHG 
FOUND., Feb. 12, 2005, http://www.phgfoundation.org/news/3148 (pointing out 
concern that gene patents hinder scientific research); Bill Seeks to Ban Gene 
Patents (National Public Radio radio broadcast Mar. 2, 2007), available at 
www.npr.org/templates/story/story.php?storyId=7689495 (discussing the im-
plications of gene patenting with Stanford Law Professor Robin Feldman, but 
not discussing potential problems with the gene concept); Sheppard Mullin, 
Bill to Prohibit Patents on Nucleic Acid Sequences Presented to U.S. House of 
Representatives, INTELLECTUAL PROPERTY LAW BLOG (June 21, 2007), 
http://www.intellectualpropertylawblog.com/archives/patents-bill-to-prohibit-
patents-on-nucleic-acid-sequences-presented-to-us-house-of-
representatives.html (discussing motivating factors behind bill, but not men-
tioning insufficiencies in gene concept. 
 175. KELLER, supra note 21, at 47 (citations omitted). 
 176. Id. 
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dustry. Gene patents contributed to the growth of the biotech-
nology industry into a huge and valuable component of the 
modern economy. 
However, the concept of the gene has increasingly been in 
jeopardy since at least the discovery of introns in the late 
1970s. Regardless of the complexity, predictability, definability, 
or even the actual existence of the gene, gene talk has been, 
and remains, a powerful form of persuasion. The biology com-
munity has relied on vigorous internal debates about gene con-
cepts continually to push back the frontiers of genetics, while 
the same community has simultaneously used gene talk autho-
ritatively to portray the gene to external constituencies as un-
controversial and relatively simple. Patent applicants, who are 
typically members of the biology community, also appear to 
have employed gene talk to assist them in securing patent 
rights in their gene, or gene-based, inventions. 
Gene talk about the particulate materiality and simple 
predictability of genes may even have subverted the view that 
members of the biology community have of genes by creating an 
incentive for patent applicants to view the process of patenting 
genes—a process rich in institutional and governmental legiti-
macy—as making the object of a patent—the gene—more sub-
stantial and real. Based on the failure of structural concepts of 
the gene, functional claiming of genes might seem a more fruit-
ful strategy for applicants seeking to patent genes. However, 
the success of gene talk may have retarded this development. 
Gene talk may be a powerful mode of communication and 
persuasion. It appears to have maintained the view of genes as 
simple and predictable enough to be patentable long after the 
biology community broadly lost faith in a single, objective, and 
relatively uncomplicated gene concept. Thus, gene talk has pre-
served the prospect of gene patents and their attendant mone-
tary rewards. Given the powerful results of, and the vast au-
thority achieved by, gene talk, it may take much longer to fade 
in influence than the concept of the gene itself. 
 
